In the product section on agilent.com you are presented with information regarding how to properly use Agilent’s Dako products (e.g. in vitro diagnostics, reagents and medical equipment) in Japan. This information is intended only for medical qualified personnel. Please note that this information is not intended for the general public.
PD-L1 IHC 28-8 pharmDx is MHLW approved assay for use in the detection of PD-L1 protein in non-squamous non-small cell lung cancer (nsNSCLC), head-and-neck cancer (HNC), melanoma, gastric cancer, and esophageal cancer
The PD-L1 IHC 28-8 pharmDx interpretation training is a comprehensive program with in-depth content and practice cases focused on helping pathologists to:
Understand the role of immune checkpoint pathways
Learn about technical considerations for optimal slide staining results
Learn how to evaluate nsNSCLC, HNC, melanoma, gastric cancer, and esophageal cancer specimens stained with
PD-L1 IHC 28-8 pharmDx
Enhanced nsNSCLC (also suitable for NSCLC), HNC, melanoma, gastric cancer, and esophageal cancer training programs with virtual microscope for increased confidence in scoring PD-L1 stained slides.
To measure the proportion of PD-L1 expression in cancer tissue or cells
Indication as an aid for proper administration of nivolumab [recombinant] in non-small cell lung cancer [NSCLC] patients,
head-and-neck cancer patients, gastric cancer patients, and esophageal cancer patients.
Indication as an aid for proper administration of nivolumab [recombinant] and ipilimumab [recombinant] combination in melanoma patients.
Important Basic Precautions
It is desirable to measure PD-L1 expression by PD-L1 IHC 28-8 pharmDx in determining whether or not the following drugs can be administered.
Nivolumab [recombinant] for the patients with non-squamous NSCLC patients or head-and-neck cancer patients who have been treated with chemotherapy previously.
Combination therapy of nivolumab [recombinant] and chemotherapy for NSCLC patients or gastric cancer patients who have not been treated with chemotherapy.
Combination therapy including nivolumab [recombinant] for esophageal cancer patients who have not been treated
Combination therapy of nivolumab [genetic recombinant] and ipilimumab [genetic recombinant] for melanoma patients and esophageal cancer patients.
If it is not possible to measure PD-L1 expression using PD-L1 IHC 28-8 pharmDx, refer to the packaging insert of the drugs, and appropriately judge the adequacy of administration.